Cargando…

Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters

Chronic hepatitis C (HCV) infection perturbs lipid and glucose metabolism. The influence of direct acting antiviral (DAA) treatment and ribavirin on these measures was evaluated. Furthermore, the effect of HCV cure on these parameters was assessed. Participants were allocated to one of three 12-week...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doyle, Mary-Anne, Galanakis, Chrissi, Mulvihill, Erin, Crawley, Angela, Cooper, Curtis L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468811/ https://www.ncbi.nlm.nih.gov/pubmed/30884773 http://dx.doi.org/10.3390/cells8030252

Ejemplares similares

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
por: Mathur, Poonam, et al.
Publicado: (2018)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
por: Graf, Christiana, et al.
Publicado: (2020)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report
por: Doyle, Mary-Anne, et al.
Publicado: (2015)

Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8(+) T-Cells in Advanced Liver Disease
por: Vranjkovic, Agatha, et al.
Publicado: (2019)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
por: Cooper, Curtis L., et al.
Publicado: (2019)

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
por: Mayor, Jennifer, et al.
Publicado: (2021)

Correction to: HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
por: Cooper, Curtis L., et al.
Publicado: (2019)

Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older
por: Parmar, Parmvir, et al.
Publicado: (2020)

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
por: Melendez-Mena, Daniel, et al.
Publicado: (2021)

Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment
por: Iossa, Domenico, et al.
Publicado: (2021)

Sensitivity of a Ribavirin Resistant Mutant of Hepatitis C Virus to Other Antiviral Drugs
por: Mihalik, Kathleen B., et al.
Publicado: (2013)

Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin
por: Derudas, Marco, et al.
Publicado: (2010)

Antiviral Activity of Ribavirin against Tilapia tilapinevirus in Fish Cells
por: Lertwanakarn, Tuchakorn, et al.
Publicado: (2021)

A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety
por: Sakamaki, Akira, et al.
Publicado: (2019)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
por: Damiani, Giovanni, et al.
Publicado: (2018)

Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals
por: Sparvoli, Jucéli Márcia Hendges, et al.
Publicado: (2023)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Disparities in direct acting antivirals uptake in HIV‐hepatitis C co‐infected populations in Canada
por: Saeed, Sahar, et al.
Publicado: (2017)

In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates
por: Giuliani, Alessandro, et al.
Publicado: (2018)

Antiviral effect of copper chloride on feline calicivirus and synergy with ribavirin in vitro
por: Li, Dengliang, et al.
Publicado: (2020)

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

In vitro antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus
por: Lee, Myung Jin, et al.
Publicado: (2017)

Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation
por: Ding, Xianting, et al.
Publicado: (2019)

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care
por: Rossi, Carmine, et al.
Publicado: (2019)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
por: Chen, Zhi-wei, et al.
Publicado: (2017)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

Influenza Antiviral Subversion: Now the Host Is in on the Act
por: Yepsen, Erin N., et al.
Publicado: (2021)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

The photolytic behavior of COVID-19 antivirals ribavirin in natural waters and the increased environmental risk
por: Guo, Ziwei, et al.
Publicado: (2023)

Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients
por: Cheng, Chun-Han, et al.
Publicado: (2022)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection
por: Druyts, Eric, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p5cn0es5jtm18ffc64ss6e3ta6